Drugs / OTSA101-DTPA-111In
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04176016 | Jan 2020 → Jan 2024 | synovial sarcoma | OncoTherapy Science, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTSA101-DTPA-111In | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04176016 ↗ |
| Modality | Monoclonal antibody | “an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody” NCT04176016 ↗ |
| Route | Intravenous | “single IV injection” NCT04176016 ↗ |
| Target | FZD10 | “Anti-Frizzled Homolog 10 (FZD10)” NCT04176016 ↗ |